FindTrial
Sign In

Daratumumab Injection

DRUG14 trials

Sponsors

Alliance Foundation Trials, LLC., Marc L Gordon, MD, H. Lee Moffitt Cancer Center and Research Institute, University of Arkansas, Ostfold Hospital Trust

Conditions

AL AmyloidosisALL, AdultAlzheimer DiseaseITPImmune ThrombocytopeniaMultiple MyelomaMyeloma, MultiplePOEMS Syndrome

Phase 1

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
RecruitingNCT05451771
Rajshekhar Chakraborty, MDAL Amyloidosis
Start: 2022-10-26End: 2026-09-30Target: 53Updated: 2025-07-08
Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders
RecruitingNCT07075510
University of Maryland, BaltimorePlasma Cell Disorder
Start: 2025-10-23End: 2032-10-01Target: 30Updated: 2025-10-29

Phase 2

Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM
Active, not recruitingNCT04009109
Alliance Foundation Trials, LLC.Myeloma, Multiple
Start: 2020-10-21End: 2027-06-30Updated: 2025-12-18
Study of Daratumumab in Patients With Mild to Moderate Alzheimer's Disease
CompletedNCT04070378
Marc L Gordon, MDAlzheimer Disease
Start: 2019-11-06End: 2023-08-15Updated: 2025-11-14
Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma
Active, not recruitingNCT04151667
H. Lee Moffitt Cancer Center and Research InstituteMultiple Myeloma
Start: 2019-11-22End: 2026-05-07Updated: 2026-03-11
Treatment of POEMS Syndrome With Daratumumab
CompletedNCT04396496
University of ArkansasPOEMS Syndrome
Start: 2020-09-22End: 2023-10-16Updated: 2023-11-13
The DART Study- Daratumumab Treatment in ITP
NCT04703621
Ostfold Hospital TrustITP
Start: 2021-01-21End: 2024-12-31Target: 21Updated: 2024-04-09
An Open Label Study to Evaluate Daratumumab in Participants With Moderate to Severe Systemic Lupus Erythematosus
NCT04810754
Charite University, Berlin, GermanySystemic Lupus Erythematosus
Start: 2021-06-30End: 2023-12-31Target: 10Updated: 2021-03-23
A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune Thrombocytopenia
Active, not recruitingNCT05562882
Institute of Hematology & Blood Diseases Hospital, ChinaImmune Thrombocytopenia
Start: 2022-12-10End: 2025-12-31Target: 60Updated: 2025-05-28
Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy
Not yet recruitingNCT06570915
Institute of Hematology & Blood Diseases Hospital, ChinaALL, Adult
Start: 2025-12-01End: 2028-09-01Target: 20Updated: 2025-10-01
Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP)
RecruitingNCT06838962
Institute of Hematology & Blood Diseases Hospital, ChinaImmune Thrombocytopenia, Treatment
Start: 2024-08-01End: 2026-08-31Target: 30Updated: 2025-08-05
Use of a New Medicine Daratumumab to Treat Left-over Cancer in a Blood Cancer Called T Acute Lymphoblastic Leukemia
RecruitingNCT07021677
Tata Memorial CentreT Acute Lymphoblastic Leukemia
Start: 2023-08-28End: 2026-08-28Target: 18Updated: 2025-06-15
Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP)
RecruitingNCT07063199
Institute of Hematology & Blood Diseases Hospital, ChinaImmune Thrombocytopenia, Treatment
Start: 2025-08-31End: 2026-08-31Target: 30Updated: 2025-07-14

Phase 3

FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)
RecruitingNCT06187441
Stichting Hemato-Oncologie voor Volwassenen NederlandMultiple Myeloma
Start: 2024-05-14End: 2037-12-31Target: 599Updated: 2024-08-19

Related Papers

Daratumumab in systemic lupus erythematosus: a single-arm phase 2 trial
Nature Communications2026-02-03
Safety and efficacy of daratumumab in immune thrombocytopenia.
2026-01-01
A randomized phase II study of daratumumab, lenalidomide, ixazomib, and dexamethasone in transplant-ineligible or deferred patients with newly diagnosed multiple myeloma: Alliance Foundation Trial 41 (AFT-41)
Blood2025-11-03
Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy
Blood2025-09-222 citations
AL Amyloidosis: Current Treatment and Outcomes.
2025-03-032 citations
De Novo Resistance and Relapse from Daratumumab Monotherapy in NDMM Is Associated with Immune Evasion and Immunosuppression
Blood2024-11-051 citations
PB2313: DARATUMUMAB AS A TREATMENT FOR ADULT IMMUNE THROMBOCYTOPENIA: A PHASE II STUDY WITH SAFETY RUN-IN (THE DART STUDY)
HemaSphere2022-06-018 citations
Daratumumab As a Treatment for Adult Immune Thrombocytopenia: A Phase II Study with Safety Run-in (the DART Study)
Blood2021-11-0513 citations
A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (AFT-41)
Blood2021-11-054 citations